Cure8 news brief
Perianal fistulas are a challenging complication of Crohn’s disease with limited effective options; a phase 3 trial reports that guselkumab improved fistula remission rates through 48 weeks, which could offer a new treatment option if findings are confirmed and adopted into practice.
Adults with Crohn’s disease and perianal fistulas, clinicians treating complex Crohn’s disease, and researchers studying biologic therapies for fistulizing IBD.
The randomized, double-blind, placebo-controlled FUZION trial enrolled adults with at least one actively draining perianal fistula and prior inadequate responses to steroids, immunomodulators, antibiotics, and up to two advanced therapy classes.
Participants were randomized to guselkumab 200 mg every 4 weeks, guselkumab 100 mg every 8 weeks, or placebo; the primary endpoint combined both guselkumab doses at 24 weeks and responders continued treatment to week 48.
At 24 weeks the trial met its primary endpoint (28% vs 10% fistula remission vs placebo); fistula remission rose to 31% at 48 weeks, and clinically defined fistula response also increased over time. Guselkumab was generally well tolerated with comparable adverse event rates to placebo in the report.
Report summarizes a conference presentation (UEG Week 2026) covered by MedNet; this is not a full peer-reviewed publication. The placebo group switched to active drug at 24 weeks, and longer-term randomized comparisons are limited. Individual treatment decisions should be made with a clinician.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
These Phase 3 results suggest guselkumab (TREMFYA) may provide durable clinical and endoscopic benefit through three years for adults with moderate to severe Crohn’s disease and may help with perianal fistula...
Perianal fistulas are a common and debilitating complication of Crohn’s disease that often need medical and surgical care. A Phase 3 trial reporting improved fistula remission with an IL-23–targeting therapy could offer...
Cure8 could only read part of this source from finance.yahoo.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.
